

‘Therapies for acute decompensation of cirrhosis and ACLF, research needs and outlook’

**ELPA presents:
DECISION, MICROB-PREDICT and A-TANGO
online educational event for patients
on 9th June 2021, 3.30 - 5.00 p.m. CEST**

Organizing committee:

Marko Korenjak, ELPA President

Prof. Dr. Pierre-Emmanuel Rautou, professor of Hepatology Hôpital Beaujon, Inserm UMR, France, principal investigator DECISION, EF Clif, Barcelona, Spain

Prof. Dr. Jonel Trebicka, professor of Hepatology Goethe University Frankfurt, Germany, principal investigator MICROB-PREDICT, EF Clif, Barcelona, Spain

Prof. Dr. Rajiv Jalan, professor of Hepatology University College London, UK, principal investigator A-TANGO, EF Clif, Barcelona, Spain

Dr. Ameli Schwalber, concentris research management, Germany, project management office

Dear representatives of the national patients' associations,

We kindly invite you to the online educational event for patients of the DECISION, MICROB-PREDICT and A-TANGO project, on Wednesday June 9th, 03:30-05:00 PM, available via [Zoom](#). Please register [here](#).

Three EU-funded research projects, MICROB-PREDICT, DECISION and A-TANGO, join forces to improve the prevention and treatment of cirrhosis. All three consortia aim to better understand the disease, identify biomarkers and mechanisms that predict when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and patient's individual treatment response. They strive to develop novel diagnostic tools, based on the newly identified biomarkers, for earlier and better patient stratification and to establish personalized and effective treatment strategies. In MICROB-PREDICT, the focus thereby lies on microbiome-based strategies. DECISION aims to identify new combinatorial therapies and A-TANGO will investigate one specific, promising substance in a clinical trial. We would like to inform you on the projects and their implications for the future management of patients with cirrhosis. We would like to discuss with you how to best disseminate this information in the national patient associations. We look forward to meeting you virtually at June 9th!

On behalf of the organizing committee,

Marko Korenjak, ELPA President

Programme:

Chairs: M. Korenjak, R. Jalan

15:30-15:50	Overview of existing therapies, drugs and research needs (DECISION, Pierre-Emmanuel Rautou)
15:50-16:10	Candidates/pathways/targets that will be important in future, e.g gut-liver axis, microbiota (MICROB-PREDICT, Jonel Trebicka)
16:10-16:30	G-TAK as a promising drug candidate (A-TANGO, Cornelius Engelmann and Rajiv Jalan)
16:30-17:00	Questions and answers (moderated by Marko Korenjak)

www.decision-for-liver.eu

www.microb-predict.eu

www.a-tango.eu

Contact

ELPA Office
Organizer
office@elpa.eu

Prof. Dr. Jonel Trebicka
MICROB-PREDICT Project coordinator
jonel.trebicka@efclif.com
+34 (0) 932 271 411

Prof. Dr. Rajiv Jalan
A-TANGO Project coordinator
rajiv.jalan@efclif.com
+44 20 7433 2795

Prof. Dr. Pierre-Emmanuel Rautou
DECISION Project coordinator
pierre-emmanuel.rautou@inserm.fr
+ 33 (0) 140 875 283

concentris research management
Project & Dissemination management
contact@concentris.de
+49 (0) 8141 6252 8571

Funding

DECISION, MICROB-PREDICT and A-TANGO receive funding from the *European Union's Horizon 2020 research and innovation programme* under grant agreements No. 847949, 825694 and 945096. This reflects only the view of the authors, and the *European Commission* is not responsible for any use that may be made of the information it contains. Reproduction is authorised provided the source is acknowledged.

